Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (101-110 of 238) with videos related to

Pageof 24
Sort By:
Clinical Therapeutics|October 8, 2013
Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjectsDaniela Baldoni, Alison Mackie, Marcelo Gutierrez, et al.
Drug Design, Development and Therapy|April 10, 2019
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjectsPatricia N Sidharta, Meggane Melchior, Martin K Kankam, et al.
European Journal of Clinical Pharmacology|January 25, 2014
Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhageJochen Zisowsky, Eliane Fuseau, Shirin Bruderer, et al.
The AAPS Journal|August 5, 2020
Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist ClazosentanPierre-Eric Juif, Jasper Dingemanse, Christine Voors-Pette, et al.
Journal of Clinical Pharmacology|May 27, 2024
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3AMassimo Magliocca, Benjamin Berger, Vincent Lemoine, et al.
Expert Opinion on Drug Metabolism & Toxicology|September 9, 2020
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disordersClemens Muehlan, Cedric Vaillant, Isabelle Zenklusen, et al.
CNS Drugs|January 30, 2020
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic DrugMuriel Richard, Priska Kaufmann, Marion Ort, et al.
Clinical Therapeutics|April 12, 2016
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male SubjectsShirin Bruderer, Kaori Okubo, Hideya Mukai, et al.
European Journal of Clinical Pharmacology|December 24, 2013
Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptiveMaribel Reyes, Patrick Brossard, Didier Chassard, et al.
International Journal of Molecular Sciences|December 11, 2022
Lack of Effect of Cenerimod, a Selective S1P<sub>1</sub> Receptor Modulator, on the Pharmacokinetics of a Combined Oral ContraceptivePierre-Eric Juif, Markus S Mueller, Hakim Charfi, et al.
Pageof 24

Showing results (101-110 of 238) with videos related to

Sort By:
Pageof 24
Clinical Therapeutics|October 8, 2013
Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjectsDaniela Baldoni, Alison Mackie, Marcelo Gutierrez, et al.
Drug Design, Development and Therapy|April 10, 2019
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjectsPatricia N Sidharta, Meggane Melchior, Martin K Kankam, et al.
European Journal of Clinical Pharmacology|January 25, 2014
Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhageJochen Zisowsky, Eliane Fuseau, Shirin Bruderer, et al.
The AAPS Journal|August 5, 2020
Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist ClazosentanPierre-Eric Juif, Jasper Dingemanse, Christine Voors-Pette, et al.
Journal of Clinical Pharmacology|May 27, 2024
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3AMassimo Magliocca, Benjamin Berger, Vincent Lemoine, et al.
Expert Opinion on Drug Metabolism & Toxicology|September 9, 2020
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disordersClemens Muehlan, Cedric Vaillant, Isabelle Zenklusen, et al.
CNS Drugs|January 30, 2020
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic DrugMuriel Richard, Priska Kaufmann, Marion Ort, et al.
Clinical Therapeutics|April 12, 2016
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male SubjectsShirin Bruderer, Kaori Okubo, Hideya Mukai, et al.
European Journal of Clinical Pharmacology|December 24, 2013
Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptiveMaribel Reyes, Patrick Brossard, Didier Chassard, et al.
International Journal of Molecular Sciences|December 11, 2022
Lack of Effect of Cenerimod, a Selective S1P<sub>1</sub> Receptor Modulator, on the Pharmacokinetics of a Combined Oral ContraceptivePierre-Eric Juif, Markus S Mueller, Hakim Charfi, et al.
Pageof 24